Collectively, blocking CD47 in the absence of effector function, did not result in efficient clearance of AML disease and did not provide a survival advantage, while effector function competent IgG1 C47B222-(CHO) demonstrated anti-leukemic efficacy. This evidence concerns the gene CD47 and acute myeloid leukemia.